These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 8542950)

  • 1. A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation.
    Smith RJ; Sweetenham JW
    Exp Hematol; 1995 Dec; 23(14):1581-8. PubMed ID: 8542950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
    Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
    Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
    Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
    Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
    Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W
    Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
    Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
    Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
    Mahendra P; Johnson D; Scott MA; Jestice HK; Hood IM; Ager S; Bass G; Barker P; Boraks PA; Bloxham DM; Baglin TP; Marcus RE
    Bone Marrow Transplant; 1996 Apr; 17(4):503-7. PubMed ID: 8722346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
    Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
    Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor.
    Bellido M; Sureda A; Martino R; Madoz P; García J; Brunet S
    Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.
    Hohaus S; Goldschmidt H; Ehrhardt R; Haas R
    Exp Hematol; 1993 Apr; 21(4):508-14. PubMed ID: 7681782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization.
    Vela-Ojeda J; Tripp-Villanueva F; Montiel-Cervantes L; Sánchez-Cortés E; Ayala-Sánchez M; Guevara-Moreno ME; García-León LD; Rosas-Cabral A; Esparza MA; González-Llaven J
    Bone Marrow Transplant; 2000 Jun; 25(11):1141-6. PubMed ID: 10849526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mobilization of peripheral blood progenitor cells by high-dose Ara C, VP-16 and recombinant human granulocyte colony-stimulating factor: factors affecting progenitor cell yields.
    Shimazaki C; Yamagata N; Tatsumi T; Hirata T; Oku N; Ashihara E; Goto H; Inaba T; Fujita N; Haruyama H
    Bone Marrow Transplant; 1995 May; 15(5):763-7. PubMed ID: 7545490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.
    Brice P; Marolleau JP; Dombret H; Lepage E; Baruchel A; Adam M; Miclea JM; Sitthy X; Gisselbrecht C
    Bone Marrow Transplant; 1992 May; 9(5):337-42. PubMed ID: 1352162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
    Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
    Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.
    Alegre A; Tomás JF; Martínez-Chamorro C; Gil-Fernández JJ; Fernández-Villalta MJ; Arranz R; Díaz MA; Granda A; Bernardo MR; Escudero A; López-Lorenzo JL; Fernández-Rañada JM
    Bone Marrow Transplant; 1997 Aug; 20(3):211-7. PubMed ID: 9257889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest.
    Haas R; Hohaus S; Egerer G; Ehrhardt R; Witt B; Hunstein W
    Bone Marrow Transplant; 1992 Jun; 9(6):459-65. PubMed ID: 1352717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. G-CSF (filgrastim)-stimulated whole blood kept unprocessed at 4 degrees C does support a BEAM-like regimen in bad-risk lymphoma.
    Ossenkoppele GJ; Schuurhuis GJ; Jonkhoff AR; Dräger AM; Westra G; Oberink JW; Legdeur MC; de Kreuk AM; Zweegman S; Huijgens PC
    Bone Marrow Transplant; 1996 Aug; 18(2):427-31. PubMed ID: 8864457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.